Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company addressing significant unmet needs in hormone-driven oncology and rare diseases. As a dual-focused innovator, we are committed to advancing therapies and improving patient care for those suffering from hormone-driven conditions.
How We’re Doing it
At Atossa Therapeutics, our clinical platform is centered around the next-generation selective estrogen receptor modulator/degrader (SERM/D), (Z)-endoxifen.
Building on our established foundation in breast cancer, we are leveraging the pro-estrogenic or anti-estrogenic attributes of SERM/D compound to expand our clinical research and developments beyond breast cancer and into rare diseases such as McCune-Albright Syndrome and Duchenne Muscular Dystrophy.
Through this approach, we aim to apply well-characterized mechanisms across ER+ breast cancer and rare diseases to improve patient outcomes and broaden therapeutic options for patients.